Table 1 Baseline characteristics of patients
| Â | MSD | UD | p value |
|---|---|---|---|
Size, n | 660 | 381 | Â |
Centers, n | 199 | 104 | Â |
Median follow-up, months (range) | 48 (40.1–157) | 30 (27-36) | 0.04 |
Year of Tx (range) | 2007 (2000–13) | 2010 (2000–13) | <10−5 |
Interval diagnosis to Tx, day (range) | 110 (60–180) | 111 (60–178) | 0.33 |
Patient sex, n (%) | |||
 Male | 393 (59.5) | 212 (55.8) | 0.24 |
 Female | 267 (40.5) | 168 (44.2) |  |
Donor sex, n (%) | |||
 Male | 347 (53) | 253 (71) | <10−5 |
 Female | 308 (47) | 103 (29) |  |
Cytogenetics, n (%) | Â | Â | 0.02 |
 Good | 13 (4.9) | 4 (2.9) |  |
 intermediate | 170 (64.2) | 71 (51.8) |  |
 Poor | 82 (30.9) | 62 (45.3) |  |
 Unknown/failed | 395 | 244 |  |
KPS, n (%) | |||
 <90% | 183 (29.8%) | 119 (33%) | 0.30 |
 ≥90% | 431 (70.2%) | 242 (67%) |  |
Female D to male R, n (%) | |||
 No | 467 (71.3) | 306 (86.2) | <10−5 |
 Yes | 188 (28.7) | 49 (13.8) |  |
CMV patient, n (%) | Â | Â | Â |
 Negative | 162 (30.5) | 148 (40) | 0.003 |
 Positive | 369 (69.5) | 222 (60) |  |
CMV donor, n (%) | |||
 Negative | 203 (38.8) | 204 (54.4) | <10−5 |
 Positive | 320 (61.2) | 171 (45.6) |  |
Source of stem cell, n (%) | |||
 BM | 53 (8) | 20 | 0.09 |
 PBSC | 607 (92) | 361 (94.8) |  |
Conditioning regimen, n (%) | |||
 MAC | 373 (56.5) | 169 (44.4) | <10−4 |
 RIC | 193 (29.2) | 93 (24.4) |  |
 Sequential strategy | 94 (14.3) | 119 (31.2) |  |
In vivo T depletion, n (%) | |||
 No | 357 (65.6) | 73 (19.5) | <10−5 |
 Yes | 187 (34.4) | 302 (80.5) |  |
GVHD prophylaxis, n (%) | |||
 CsA alone | 85 (12.9) | 44 (11.5) |  |
 CsA+ MTX | 256 (38.8) | 93 (24.5) |  |
 CsA+ MMF + other | 165 (25) | 194 (50.9) |  |